Drug Development

Nov 20, 2017
By Pharmaceutical Technology Editors
The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.
Nov 20, 2017
By Pharmaceutical Technology Editors
The opnME.com platform offers scientists access to best-in-class molecules supported by comprehensive data packages.
Nov 20, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Avista Pharma Solutions facility and equipment upgrades at its Longmont, Colorado facility support processing of potent compounds.
Nov 16, 2017
By Pharmaceutical Technology Editors
Bayer will make a $400-million upfront payment to develop and commercialize two anti-cancer compounds in Loxo Oncology’s portfolio.
Nov 16, 2017
By Pharmaceutical Technology Editors
As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.
Nov 15, 2017
Pharmaceutical Technology
The use of approved platform technologies can reduce the time and cost required to generate new vaccines.
Nov 15, 2017
Pharmaceutical Technology
Despite the challenges and high cost of development, vaccine innovation is at an all-time high, as new approaches aim to improve global access.
Nov 15, 2017
Pharmaceutical Technology
Challenge trials may increase in coming years as new and improved challenge agents better emulate “natural” disease states.
Nov 15, 2017
Pharmaceutical Technology
The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.
Nov 14, 2017
By Pharmaceutical Technology Editors
ADC Bio experts warn of impending problems in the ADC pipeline with millions wasted in development costs.
native1_300x100
lorem ipsum